Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP3 | O14638 | 3/20 | 0.41 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 7/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 5/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | BRAF | P15056 | 1/20 | 0.35 |
| ▸ | MITF | O75030 | 1/20 | 0.35 |
| ▸ | STAT3 | P40763 | 1/20 | 0.35 |
| ▸ | STAT1 | P42224 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | ATP4A | P20648 | 1/20 | 0.34 |
| ▸ | ATP4B | P51164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3179659 | 0.84 | ENPP3 (0.59) | ENPP3ENPP1RAB9AALDH1A1KMT2A | |
| SCHEMBL19625366 | 0.82 | LTA4H (0.47) | ENPP3ENPP1RAB9AALDH1A1KMT2A | |
| SCHEMBL20286120 | 0.81 | ENPP3 (0.45) | ENPP3ENPP1RAB9AKMT2A | |
| SCHEMBL3993786 | 0.77 | KMO (0.38) | RAB9AALDH1A1KMT2ANPC1LMNA | |
| SCHEMBL19625391 | 0.76 | TP53 (0.46) | ENPP3ENPP1RAB9AALDH1A1KMT2A | |
| SCHEMBL6986241 | 0.76 | ENPP3 (0.69) | ENPP3ENPP1RAB9AKMT2ANPC1 | |
| SCHEMBL20286125 | 0.72 | NPC1 (0.40) | RAB9AKMT2ANPC1L3MBTL1SMN1; SMN2 | |
| SCHEMBL3637967 | 0.72 | RAB9A (0.44) | ENPP3ENPP1RAB9AALDH1A1ALOX5 | |
| SCHEMBL3991408 | 0.71 | ENPP3 (0.41) | ENPP3ENPP1RAB9AALDH1A1ALOX5 | |
| SCHEMBL27009164 | 0.71 | ENPP3 (0.56) | ENPP3ENPP1RAB9ANPC1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200048268-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-02-13 | — | — | US | disclosed |
| US-20180170941-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | HAGER BIOSCIENCES | 2018-06-21 | — | — | US | disclosed |
| US-20180170941-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | HAGER BIOSCIENCES | 2018-06-21 | — | — | US | disclosed |
| US-7863310-B2 | Kinase inhibitors | ELI LILLY AND COMPANY (US) | 2011-01-04 | — | — | US | disclosed |
| US-20090318443-A1 | KINASE INHIBITORS | BONJOUKLIAN ROSANNE | 2009-12-24 | — | — | US | disclosed |
| US-7582652-B2 | Suppression cytokines, tumor necrosis factor; melanoma | ELI LILLY AND COMPANY (US) | 2009-09-01 | — | — | US | disclosed |
| EP-1713805-B1 | KINASE INHIBITORS | LILLY CO ELI (US) | 2009-06-10 | — | — | EP | disclosed |
| US-20090036445-A1 | KINASE INHIBITORS | ELI LILLY AND COMPANY | 2009-02-05 | — | — | US | disclosed |
| US-20080227839-A1 | Kinase Inhibitors | ELI LILLY AND COMPANY | 2008-09-18 | — | — | US | disclosed |
| EP-1720862-A1 | KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-11-15 | — | — | EP | disclosed |
| EP-1713805-A1 | KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005080380-A1 | KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-09-01 | — | — | WO | disclosed |
| WO-2005075478-A1 | KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036445-A1 | KINASE INHIBITORS | MAP3K20, MAP3K19, MAP3K1 | ENPP3 1774/4885ENPP1 1402/4885RAB9A 2018/4885 |
| US-20090318443-A1 | KINASE INHIBITORS | MAP3K20, MAP3K19, MAP3K1 | ENPP3 1774/4885ENPP1 1402/4885RAB9A 2018/4885 |
| US-20180170941-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | GRM5, GABRA5, GABRE | ENPP3 4659/4885ENPP1 4616/4885RAB9A 397/4885 |
| US-20080227839-A1 | Kinase Inhibitors | ABL1, MAP3K20, MAP3K19 | ENPP3 2032/4885ENPP1 1751/4885RAB9A 1892/4885 |
| US-20200048268-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | GABRA5, GRM5, GABRA1 | ENPP3 4668/4885ENPP1 4583/4885RAB9A 646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.